Shares of Kura Oncology (KURA) have gained 5.6% over the past four weeks to close the last trading session at $11.28, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $31.42 indicates a potential upside of 178.6%.

The mean estimate comprises 12 short-term price targets with a standard deviation of $15.62. While the lowest estimate of $15.00 indicates a 33% increase from the current price level, the most optimistic analyst expects the stock to surge 573.8% to reach $76.00. It's very important to note the standard deviation here, as it helps understand the variability of the estimates. The smaller the standard deviation, the greater the agreement among analysts.

Originally published on zacks.com, part of the BLOX Digital Content Exchange.

(0) comments

Welcome to the discussion.

Keep it Clean. Please avoid obscene, vulgar, lewd, racist or sexually-oriented language.
PLEASE TURN OFF YOUR CAPS LOCK.
Don't Threaten. Threats of harming another person will not be tolerated.
Be Truthful. Don't knowingly lie about anyone or anything.
Be Nice. No racism, sexism or any sort of -ism that is degrading to another person.
Be Proactive. Use the 'Report' link on each comment to let us know of abusive posts.
Share with Us. We'd love to hear eyewitness accounts, the history behind an article.